{
    "nct_id": "NCT03189706",
    "official_title": "Phase II Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma",
    "inclusion_criteria": "* Diagnosis of NB as defined by international criteria,.e., histopathology (confirmed by the MSK Department of Pathology) or bone marrow metastases plus high urine catecholamine levels\n* High-risk NB as defined as any of the following:\n\n  * Stage 4 with MYCN amplification (any age)\n  * Stage 4 without MYCN amplification (>1.5 years of age)\n  * Stage 3 with MYCN amplification (unresectable; any age)\n  * Stage 4S with MYCN amplification (any age)\n* Patients fulfill one of the following criteria:\n\n  1. Have evidence of soft tissue disease OR\n  2. If they only have osteomedullary disease at protocol enrollment, they should have:\n\n     * Had previously received Hu3F8+GMCSF therapy AND have had less than a complete response to it OR\n     * Had progressed progressive disease after their most recent anti-neuroblastoma therapeutic regimen\n* Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive MIBG or PET scans) or measurable (CT, MRI) disease documented after completion of prior systemic therapy.\n* Prior treatment with murine and hu3F8 is allowed.\n* Prior treatment with irinotecan or temozolomide is permitted.\n* Patients with prior m3F8, hu3F8, ch14.18 or hu14.18 treatment must have a negative HAHA antibody titer. Human anti-mouse antibody positivity is allowed.\n* Signed informed consent indicating awareness of the investigational nature of this program.\nHealthy volunteers allowed",
    "exclusion_criteria": "* Patients with CR/VGPR disease\n* Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity â‰¥ grade 3 except for hearing loss, alopecia, anorexia, nausea, and hypomagnesemia from TPN, which may be grade 3\n* ANC < 500/uL\n* Platelet count <30K/uL\n* History of allergy to mouse proteins\n* Active life-threatening infection\n* Inability to comply with protocol requirements\n* Women who are pregnant or breast-feeding",
    "miscellaneous_criteria": ""
}